Proteins and Peptides
26 April 2019
Novo Nordisk files for EU regulatory approval of oral semaglutide for the treatment of type 2 diabetes23 April 2019
Akari Therapeutics Announces Positive Initial Phase II Clinical Data in Orphan Skin Disease Bullous Pemphigoid12 April 2019
89bio Announces Preclinical Data That Demonstrate Potential Utility of BIO89-100 for Treatment of NASH9 April 2019
PhaseBio Announces Global License of PB1023 for the Treatment of Sarcopenia-Related Diseases to ImmunoForge3 April 2019
Allergan and Molecular Partners Announce Topline Safety Results from MAPLE study of Abicipar pegol26 March 2019
Promedior Received Breakthrough Therapy Designation from FDA for PRM-151 in Idiopathic Pulmonary Fibrosis20 March 2019
Arch Biopartners Receives Approval to Perform Phase I Clinical Trial for Metablok in Australia19 March 2019
Alkahest Doses First Subject in Phase 2 Clinical Trial of Lead Candidate in Patients with Severe Alzheimer’s Disease15 March 2019
ImmunogenX Initiates Phase 2 Trial for its Lead Therapeutic and Diagnostic Candidates Latiglutenase and CypCel7 March 2019
Baxter Announces U.S. FDA Approval and Launch of Ready-to-Use Cardiovascular Medicine Eptifibatide5 March 2019
Lilly to Introduce Lower-Priced InsulinNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports